After being informed of the study and the potential risks, all patients matching the eligibility criteria and who have given their written consent will undergo a gel injection at day 0 after a period of screening of up to 14 days.~Then, they will be followed-up for a variable period according to the cohort :~first cohort of 5 patients with only one disc to be treated will be followed during 48 weeks,~second cohort of 5 patients with 2 discs to be treated will be followed during 36 weeks,~third cohort of 10 patients with 1 or 2 discs to be treated will be followed during 24 weeks.
The purpose of this study is to assess the safety and the efficacy of an hydrogel (double cross-link microgel - DXM) injection into the intervertebral disc (IVD) space in patients with painful lumbar degenerative disc disease (DDD) over 24 to 48 weeks.